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Objective: We evaluated the short and long-term effect of peri-interventional dabigatran
therapy on vasomotion, endothelialization, and neointimal formation in a porcine coronary
artery stenting model.
Background: Stenting of coronary arteries induces local inflammation, impairs
vasomotion and delays endothelialization.
Methods: Twenty-eight animals underwent percutaneous coronary intervention (PCI)
with drug eluting stents. Sixteen pigs started dabigatran therapy 4 days prior to PCI and
continued for 4 days post-stenting, while 12 animals served as controls. Post-stenting
dual antiplatelet therapy (75mg clopidogrel and 100mg aspirin) was continued in both
groups until termination. Immediately post-stenting and at day 3 optical coherence
tomography (OCT) was performed in all animals, followed by euthanasia of 8 dabigatran
and 4 control animals. The remaining pigs (8 of each group) were followed up for
1 month, with control angiography and OCT. Tissue burden (degree of peri-strut
structure—thrombus and/or fibrin) was evaluated. After euthanasia coronary arteries
were harvested for in-vitro myometry and histology.
Results: Thrombin generation was lower (p < 0.001) and tissue burden (0.83 ± 0.98
vs. 3.0 ± 2.45; p = 0.031) was significantly decreased in dabigatran treated
animals. After 3 days post-PCI endothelium-dependent vasodilation was significantly
improved (77 ± 40% vs. 41 ± 31%, p = 0.02) in dabigatran animals. Neither
quantitative angiography nor histomorphometry showed differences between the groups.
Endothelialization was faster in the dabigatran group as compared with controls
(p = 0.045).
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Conclusion: Short-term peri-interventional triple therapy with dabigatran, aspirin,
and clopidogrel led to an enhanced endothelium dependent vasodilation and faster
endothelialization. However, neointimal formation 1-month after stent implantation was
comparable between groups.
Keywords: vasomotor function, endothelialization, neointimal formation, dabigatran, preclinical
INTRODUCTION
Percutaneous coronary intervention (PCI) has evolved to the
gold standard treatment of stenotic coronary artery disease,
requiring dual antiplatelet therapy (DAPT) post-PCI (1).
However, a combination of antiplatelet and anticoagulant
therapy in patients with atherothrombotic risk has shown
favorable ischemic outcomes compared to either antiplatelet
or anticoagulant monotherapy, though with increased
bleeding (2, 3).
In contrast to the intention to prevent thromboembolic
events in patients requiring coronary intervention, short
peri-procedural triple anticoagulant therapy might reduce
the inflammatory activation with consequently decrease of
neointimal hyperplasia. Thrombin is a relevant protease of the
coagulation cascade and plays a central role in local vascular
inflammation of coronary arteries after stenting by activating
the monocyte chemoattractant factor 1 (MCP-1) and endothelial
cells, and modulates vascular tone and permeability (4). The
predominant mediator of thrombin signaling is the protease-
activated receptor-1 (PAR-1) in most cell types, including
platelets and endothelial cells (4). Therefore, our hypothesis was,
that the peri-procedural triple therapy with dabigatran reduces
the stenting associated inflammation by reducing thrombin and
potentially modifies the coronary vasomotor function at 3 days.
We were furthermore interested whether such potential early
effects might have an impact on vasomotion and neointimal
formation after 1 month.
Accordingly, the purpose of the present study was to evaluate
the anti-inflammatory and anti-stenotic effect of a short-term
peri-interventional triple therapy with dabigatran and DAPT
before and after coronary stenting with drug-eluting stents (DES)
in porcine coronary arteries.
MATERIALS AND METHODS
Animal Preparation and Drug
Administration
Twenty-eight domestic pigs (weight 32 ± 2.4 kg) were included
into the study. An animal handling protocol is provided in the
Supplementary Material. Four days prior to intervention sixteen
of the 28 animals received 20 mg/kg dabigatran p.o. twice daily
(600mg 2x/d, equivalent to 2 × 150mg human dose) to reach
a steady state in dabigatran serum therapeutic level, according
to literature data showing delayed and reduced absorption of
dabigatran in pigs (5). One day before intervention all pigs
(dabigatran group n = 16, control group n = 12) were loaded
with 300mg clopidogrel and 100mg aspirin per os. All animals
continued receiving 75mg clopidogrel and 100mg aspirin daily
until euthanasia. Animals of the dabigatran group continued the
anticoagulation with dabigatran up to 4 days post-stenting, since
MCP-1 was described to be detected up to 4 days after intimal
injury (6) (Figure 1).
At the day of PCI, anesthesia was initiated with 12 mg/kg
ketamine-hydrochloride, 1 mg/kg xylazine and 0.04 mg/kg
atropine and deepened with isofluorane and O2 via a facemask.
Following intratracheal intubation, anesthesia was continued
with a gas mixture of 2–3.5 vol% isofluorane, 1.6–2.5 vol%
O2 and 0.5 vol% N2O. Blood pressure, O2 saturation and
electrocardiogram were monitored. The right femoral artery was
surgically prepared, an arteriotomy was performed under sterile
conditions. A 7F introducer sheath (Radifocus Introducer II,
Terumo Medical Corporation, Somerset, NJ, USA) was inserted
into the artery. In all animals—in the control group as well as in
animals treated with dabigatran—unfractionated heparin (UFH)
was administered guided by activated clotting time in a range of
200–300 s.
The study was conducted in the Institute of Diagnostics
and Oncoradiology, University of Kaposvar, Hungary, and
approved by the Ethical Committee on Animal Experiments of
the University of Kaposvar, Hungary, based on the “Principle
of laboratory animal care” (NIH publication No. 86–23,
revised 1985).
Percutaneous Coronary Intervention
Guiding catheter of 7F (Medtronic, Minneapolis, MN, USA) was
introduced into the left coronary artery ostium, and coronary
angiography was performed using a nonionic contrast agent.
After placement of a guiding wire (Cordis, Miami Lake, Florida)
into the left anterior descending (LAD) and left circumflex
(LCX) coronary arteries, DES (Nobori, Terumo Europe, Leuven,
Belgium) (3.2 ± 0.3mm of diameter and 20.6 ± 5.5mm of
length) were alternatingly implanted into the LAD or the LCX,
according the guidelines of pre-clinical stenting experiments
(7). The Nobori DES is coated only abluminally with a matrix
containing Biolimus A9 and poly-lactic acid (PLA) (8).
After stenting, intravascular optical coherence tomography
[OCT] imaging was performed with the C7-XR imaging
system (St. Jude Medical, LightLab Imaging, Inc., Westford,
Massachusetts). The image catheter (DragonflyTM, St. Jude
Medical, LightLab Imaging, Inc., Westford, Massachusetts) was
advanced and positioned distal to the stented segment. A
continuous flush of contrast through the guiding catheter with
4 ml/s was used for blood clearance while a motorized pullback
was performed. The images were captured and digitally stored
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FIGURE 1 | Study design. DES, drug-eluting stent; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; DAPT, dual antiplatelet therapy;
OCT, optical coherence tomography.
by the ILUMIEN System (St. Jude Medical, St. Paul, MN) for
offline analysis.
After the procedure the introducer sheath was removed, the
arteriotomy was ligated, and the skin was closed in two layers.
The animals were then allowed to recover from the anesthesia.
Follow-Up
The first follow-up times was chosen 3 days after PCI since
thrombus burden is highest in the first 4 days after PCI (9)
and MCP-1 is upregulated in only the first 4 days after vascular
injury (6, 10, 11). The final follow-up of 1-month in pigs
matches a 6-month follow-up period in humans (7, 12, 13).
During the follow-up period the pigs received daily 100mg
aspirin and 75mg clopidogrel per os. The pigs of the dabigatran
group received additionally dabigatran for further 4 days
after intervention.
Follow-up examinations included coronary angiography,
OCT followed by explanting of the heart with the stented arteries
for in vitro myometry and histology at 3 days and 1 month.
Using 10mL of saturated potassium-chloride, 8 animals of the
dabigatran group and 4 animals of the control group were
sacrificed at day 3 follow-up, while 8 animals of each group were
sacrificed at 1-month follow-up.
The coronary arteries were dissected, the stented segments,
the proximal and distal segments adjacent to stenting were cut
and flushed with physiological saline solution.
For in-vitro measurements of vasomotor response 4mm long
rings directly proximal and distal to the stents were cut and
the measurements were performed immediately. Additionally, a
4mm long ring from the stent free RCA was harvested, in order
to have a stent free comparator.
For histopathological and histomorphometrical analysis the
stented segments of the 3-day follow-up, were cut in two parts.
One part was fixed in 4% formalin and was embedded in
Technovit 9100, while the other part was dipped in RNAlater bath
for 24 h at 4◦C and then deep frozen in −20◦C for quantitative
real time PCR (qPCR). The 1-month follow-up stents were
embedded in Technovit 9100 for histology. The plastic embedded
arteries were cut into 4- to 6µm thick slices and stained
with hematoxylin-eosin.
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Analyses
All analyses were performed blinded for the treatment group.
Quantitative Coronary Angiography
Post-stent and follow-up quantitative coronary angiography
(QCA) parameters were measured by means of a computer-
assisted quantitative arteriographic edge-detection algorithm
(ACOM.PC, Siemens, Erlangen, Germany).
OCT
Quantitative OCT measurements were performed using
LightLab Imaging software (LightLab Imaging/St. Jude Medical)
as previously described (14). A semi-quantitative score was
developed to assess peri-strut tissue burden considered as
structures on the stent strut most likely thrombus and/or fibrin
(Supplementary Figure 1). First, one proximal, mid and distal
section of the stent was chosen, where the tissue burden was
highest. Second, the tissue burden was scored, involving the
length, circumference, and thickness of peri-strut tissue. The
selected cross sections were partitioned in quadrants (a, b, c,
and d). One point per quadrat was given if a peri- strut tissue
was detected. In case of more than 50% of the circumference
within the quadrant was coated with tissue an additional point
was given. As a next step the maximal peri-stent strut tissue
thickness was measured for each strut in each quadrant, and
additional points were given for 0.21–0.3mm, 3 additional points
for 0.31–0.5mm, 4 additional points for 0.51–0.99mm, and 6
additional points for ≥1mm.
Histomorphometry and Histopathology
The methodology for histopathology and histomorphometry is
provided in the Supplementary Material.
Real Time Quantitative PCR (qPCR)
The stented coronary segments were analyzed using qPCR
to quantify the levels of MCP-1 and PAR-1. After the stent
was extracted from the artery, the tissue was transferred into
RNA later (Qiagen, Germany). The non-stented RCA served
as a reference control. mRNA was reverse transcribed to
cDNA with QIAGEN miScript RT kit (Qiagen, Germany) and
expression was quantified by qPCR with miScript SYBR R© Green
PCR Kit (Qiagen, Germany) on an Applied Biosystems 7500
Real-Time PCR System (Life Technologies, USA). Genes of
interest were selected based on suspected involvement in in-
stent restenosis development (MCP-1, PAR-1). The primers for
the target sequences were designed using Primer3 software
(http://primer3.wi.mit.edu/primer3web_help.htm; Microsynth,
Switzerland). The method of Livak and Schmittgen (15) was
used to calculate the relative expression of selected genes that
were normalized to a housekeeping gene ACTB. The expression
changes were calculated relative to expression levels in unstented
RCA calibrator samples.
Thrombin Generation Assay
Thrombin generation measurements were performed directly
before the intervention, immediately after stenting and at
day 3 follow-up. Thrombin generation was measured using a
commercially available fluorogenic assay kit (Technothrombin
TGA, Technoclone, Vienna, Austria) according to manufacturer
instructions (16). In this assay coagulation of platelet-poor
plasma samples was initiated with addition of the TGA
RC low reagent, containing a final concentration of 5 pM
recombinant human tissue factor lipidated in 3.2 µmol/l
phospholipid micelles (phosphatidylcholine [2.56 µmol/l] and
phosphatidylserine [0.64 µmol/l]). The generated thrombin
cleaves the fluorogenic substrate Z-Gly-Gly-Arg-AMC (1mM,+
15mM CaCl2) (Technoclone), while fluorescence was measured
at 360 nm extinction and 460 nm emission on the same
microplate reader over a period of 120min in 1-min intervals.
The peak thrombin was used in the analysis.
Measurements of Vasomotor Responses
Implantation of a stent, as a rigid metallic cage, results in an
altered vasomotor function of the coronary arteries, adjusted
to systolic-diastolic movement, and thus may result in an
increased shear stress with consequent vascular complications
(17). Inhibition of thrombin with consequent interruption of
thrombus formation and inflammation cascade in the first
days after stenting might have an influence on vasomotor
function. After explanting of the heart, 4mm long stent-free
arterial ring proximal and distal adjacent to the stents were
isolated, and the fat and connective tissues were removed.
The segments were mounted in a temperature-controlled 15-ml
tissue bath (37◦C) containing a commercially available, modified
Krebs–Henseleit buffer solution (K3753, Sigma-Aldrich, Vienna,
Austria), as published previously (18, 19). The buffer solution
was continuously controlled, and supplemented with fresh
solution from the reservoir dish by using a peristaltic pump
(Ismatec REGLO Digital, IDEX, Germany) to achieve a steady
state flow of 1.5 ml/min. The buffer reservoir was replenished
with 95% O2 and 5% CO2mixture, to reach a pH of 7.4. To
measure the isometric circular wall tension of the vessels,
the segments were suspended between 2 L-shaped metal
pins (0.4mm in diameter) in a myograph (LIVING SYSTEM
INSTRUMENTATION, A Division of Catamount Research
and Development, Inc. Saint Albans, VT 05478, USA). After
approximately 1 h stabilization period, the vessel segments
were maximally contracted with endothelin-1 (30 nmol/l).
Maximum endothelium-dependent vasodilation was achieved
by application of substance P (1 nmol/l) directly into the
organ bath. The sensitivity of smooth muscle to external
nitric oxide (NO) was investigated by subsequent addition of
sodium nitroprusside (4 mmol/l). The vasoconstriction, was
expressed as milliNewtons (mN). The endothelium-dependent
and endothelium-independent vasodilation (stiffness of vascular
smooth muscle after injury of PCI) were expressed in percent
change of steady-state level contraction, and in mN/s/mN units,
respectively. The vasomotion experimental setup is visualized in
our previous experiment (18).
Serological Inflammation Markers (hsCRP, IL-6,
IL-1beta) and Serological Platelet Activation Marker
sP-Selectin
Serum concentrations of porcine hsCRP, IL-6, IL-1beta, and
sP-selectin were measured using commercial enzyme-linked
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immunosorbent assay (ELISA) kits. The following kits were used
in this study: porcine hs-CRP (Cat.Nr.:E07C0087) (Biotrend,
Cologne, Germany), porcine IL-6 (Cat.Nr.: RAB0310) (Sigma-
Aldrich, St. Louis, MO, USA), swine IL-1 beta (Cat.Nr.:ESIL1B)
(Thermo Fisher Scientific, Waltham, MA, USA), pig sP-selectin
(Cat.Nr.: CSB-E08106p) (Cusabio, Hubei, China). All assays were
performed according to the manufacturer’s instructions.
Statistics
The continuous parameters were expressed as means± standard
deviation (SD). The differences between the groups were
analyzed by Student t-test. Statistical analyses were carried out
using SPSS software (version 23.0, SPSS, IBM Corporation, NY,
USA). A p < 0.05 was considered statistically significant.
RESULTS
Under the triple therapy with aspirin, clopidogrel and dabigatran
(plus unfractionated heparin during the PCI procedure) one
animal suffered from a hematoma at the groin at day 3 follow-up
TABLE 1 | Optical coherence tomography (OCT) results of the tissue burden
score immediately after coronary stenting and at day 3 follow-up.
Immediately after stenting 3 Days post-stenting
Dabigatran Group 0.83 ± 0.98 6.87 ± 2.26
Control Group 3.0 ± 2.45 7.8 ± 3.39
p-value 0.031 0.42
Means ± SD.
with a hemoglobin drop of 4.4 g/dl. Vital parameters were stable
without tachycardia or hemodynamic compromise.
Thrombin Assay
The anticoagulant effect of dabigatran in the pigs was
measured using thrombin generation, directly before (after 4-
days treatment with dabigatran in dabigatran group and in
controls) and directly (30min) after the intervention, and at day
3 follow-up. Dabigatran-treated animals had significantly lower
thrombin peak levels before the stenting and at 3-days follow-up
than controls (Supplementary Figure 2).
QCA
QCA parameters at baseline, after the intervention, at day 3
follow-up and at 1 month follow-up did not differ significantly
between the groups (Supplementary Table 1).
OCT
Quantitative morphometric OCT parameters were not
significantly different in the groups (Supplementary Table 2). In
contrast, the tissue burden on the stent struts was significantly
lower directly after the intervention in animals treated with
dabigatran than in controls. This effect did not last to day 3
follow-up (Table 1).
Histomorphometry and Histopathology
Similar to QCA and OCT, histomorphometrical results did not
differ between the groups (Supplementary Tables 1–3).
Injury score did not differ between the groups. The
histopathological data did not show significant differences
between the groups in inflammation or fibrin deposition at
day 3 and 1-month follow-up. However, animals treated with
TABLE 2 | Histopathologic results.
Inflammation Fibrin deposition Endothelialization [%]
3d 1mo 3d 1mo 3d 1mo
Dabigatran Group 0.44 ± 0.73 0.43 ± 0.79 2.22 ± 0.97 2.14 ± 1.57 44.44 ± 20.83 100 ± 0
Control Group 0.50 ± 0.58 0.25 ± 0.46 3.00 ± 0.82 2.38 ±1.19 18.75 ±12.50 78.13 ±33.91
p-value 0.90 0.60 0.19 0.75 0.045 0.11
3d, 3-day follow-up; 1mo, 1-month follow-up, Means ± SD.
FIGURE 2 | Representative histologic illustration of the tissue coverage over the stent struts at day 3 after intervention with inflammation, fibrin and endothelialization.
(A) Tissue coverage over the stent struts with mainly fibrin, (B) with inflammatory cells and (C) with endothelial cells and leucocytes over the stent struts at day 3 after
intervention, regardless of the treatment arm.
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FIGURE 3 | Vasomotor diagrams of stented and non-stented coronary arteries in dabigatran and control groups. (A) Endothelin-induced vasoconstriction, (B)
Endothelium-dependent vasodilation, (C) Endothelium-independent vasodilation in non-stented (native right coronary artery) and stented (summed results of left
anterior descendent/LAD/and left circumflex/LCx/) coronary arteries at 3 days post stenting, and at the 1-month follow-up. No statistically significant differences
between the groups. Significantly enhanced endothelium-dependent vasodilation capacity at the 3-day follow-up in dabigatran group. Mean ± SD.
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dabigatran exhibited more endothelialization at day 3 and
complete endothelialization at the 1-month follow-up, indicating
a faster healing process (Table 2). As seen in Figure 2 the tissue
over the stent struts at day 3 consists of endothelial cells and
aggregated leucocytes.
Vasomotor Edge Response
The endothelin-induced vasoconstriction did not differ between
groups. At day 3 the endothelium-dependent vasodilation was
significantly enhanced in the dabigatran group, whereas the
endothelium independent vasodilation was similar in both
treatment groups (Figure 3).
qPCR of Tissue MCP-1 and PAR-1
At day 3, during dabigatran treatment the in-stent tissue MCP1
expression was significantly lower after DES implantation. In
contrast, PAR-1 expression did not show differences between the
treatment groups at day 3 follow-up (Figure 4).
Serological Inflammation Markers (hsCRP,
IL-6, IL-1beta) and Serological Platelet
Activation Marker sP-Selectin
During the triple therapy treatment with dabigatran, aspirin and
clopidogrel hsCRP and IL-6 levels did not differ significantly as
compared with the control group. However, IL-1beta levels were
in the dabigatran group significantly lower at day 3 follow-up.
FIGURE 4 | qPCR analysis of MCP-1 and PAR-1 expression of the stented
tissue 3 days after stenting in dabigatran and control groups. Mean ± SD.
The serological marker for platelet activation sP-selectin had
significantly lower levels in the dabigatran group as compared
with controls (Supplementary Table 4).
DISCUSSION
In the present study investigating the impact of dabigatran
on coronary artery inflammation and vessel healing
after PCI with DES, we are able to report the following
findings: peri-interventional treatment with dabigatran was
associated with favorable effects on endothelium dependent
vasodilatation, faster endothelialization as well as lower MCP-1
expression but comparable neointimal proliferation and
peri-strut inflammation.
Stent implantation induces vascular injury by barotrauma
associated with balloon stent inflation. Additionally foreign body
reaction to the components of the stent e.g., metal and polymer
are well known triggers for adverse vascular repair reaction with
characteristic features such as fibrin deposition, inflammation,
media necrosis and peri-strut hemorrhage (20). Dabigatran
has been shown to exert antiatherosclerotic effects in mice
(21). Furthermore, dabigatran treatment was associated with
a dose dependent suppression of pro-inflammatory cytokines
and adhesion molecules e.g., MCP-1, IL6, intercellular adhesion
molecule (ICAM-1) and vascular cell adhesion molecule 1
(VCAM-1) (22). MCP-1 expressed from vascular smooth muscle
cells (VSMC) and endothelial cells is known to enhance the
recruitment of monocytes into the vessel wall and thereby
activating an inflammatory process and subsequently increasing
the risk for adverse vascular repair response to the injury
induced by stent implantation (23, 24). Furthermore, MCP-1
has been shown to promote endothelial cell apoptosis (25). In
the present study, peri-PCI treatment with dabigatran resulted
in lower MCP-1 expression at stented segments. Taken together
with a reduction of thrombin generation, the lower MCP-1
expression might explain the observed faster endothelialization
in animals treated with dabigatran compared to control group
with subsequently significantly higher endothelium dependent
vasodilatation. In OCT we observed a lower tissue burden
on the stent struts in animals treated with dabigatran directly
after the intervention. However, this effect was not observed
after 3 days although thrombin generation remained low.
Therefore, a relationship between the lower peri-strut tissue
burden initially after the intervention and the observed favorable
effects on endothelium dependent vasodilatation or the faster
endothelialization seems to be unlikely. Previous experimental
studies however, showed that rivaroxaban, a direct inhibitor
of activated factor X (FXa), enhanced endothelial growth
and healing (26). Since thrombin and FXa have pleiotropic
effects, as they also act via protease activated receptors, their
inhibitors, both dabigatran and rivaroxaban may also have
pleiotropic effects, besides to the anticoagulant action explaining
our findings.
Safety concerns about dabigatran treatment arose as in the
RE-LY trial a trend toward a higher incidence for myocardial
infarction was observed as compared to the control group
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(27, 28). However, the frequency of these adverse events was low
and the overall benefit and risk balance of dabigatran use appears
to be favorable in patients with atrial fibrillation because of
reduction in stroke. As a consequence, guidelines do not address
this topic and do not recommend one specific NOAC over the
other in the setting of percutaneous coronary intervention (1).
Extensive research to further understand the higher incidence
of myocardial infarction has shown that dabigatran enhances
platelet reactivity. Dabigatran increased platelet reactivity by
enhancing thrombin receptor density on platelets (29). Platelet
reactivity induced by collagen, arachidonic acid and ADP was
not altered by dabigatran treatment. Further an oral thrombin
inhibitor treatment increased platelet adhesion and thrombus
formation under flow in vitro. However, this prothrombotic
effect was reversed by aspirin treatment (30). Taken together, the
concomitant therapy of dabigatran with aspirin and clopidogrel
might counteract the previously described prothrombotic effect
of dabigatran. We could demonstrate that under a triple therapy
with dabigatran, aspirin, and clopidogrel the serological marker
for platelet activation sP-selectin was significantly lower at day 3
as compared with the control group with a treatment of aspirin
and clopidogrel alone.
DES implantation in a porcine coronary artery model was
associated with long-term impaired vasomotor function
evidenced by a reduction in endothelium dependent
vasodilatation in DES but not in bare metal stent and drug
eluting balloon treated pigs (18). Similar changes were
observed in an earlier experiment using first generation
DES (31) although with more pronounced histological
markers of inflammation. In comparison to those studies,
in the present experiment, third generation DES with low
strut thickness of 111µm and biodegradable polymer was
used. Such stents were shown to be associated with favorable
outcomes compared to earlier DES platforms (8). This stent
platform was associated with preserved endothelium-dependent
vasomotion compared to first generation DES (sirolimus eluting
stent) (32). Consequently, it could be hypothesized that the
combined utilization of novel DES platform in combination
with dabigatran resulted in the favorable findings obtained in the
present study.
The findings from these pre-clinical experiments can certainly
not be directly translated into clinical practice without further
investigation. Although in the ATLAS ACS 2—TIMI 51
treatment with a Xa inhibitor rivaroxaban, in the lower dose
of 2.5mg, has been associated with a significant reduction of
ischemic events, a higher rate of bleeding complications should
be acknowledged as a major tradeoff of such treatment concept
(3). In the present study under an effective anticoagulatory dose
of dabigatran, and the treatment with aspirin and clopidogrel
one pig suffered from access site hematoma with a hemoglobin
drop of 4.4 g/dL considering it a major bleeding event.
Interestingly, an uninterrupted oral anticoagulation therapy
in patients undergoing unplanned percutaneous coronary
intervention was associated with shorter length of hospitalization
and equivalent risk for MACCE and bleeding complications
as compared to interrupted oral anticoagulation therapy (33).
Taking this data in consideration, the additional information on
faster endothelialization and enhanced endothelium-dependent
vasodilation is of interest.
LIMITATIONS
As an experimental study the presented data should be
interpreted with caution and considered hypothesis generating.
The experiment was conducted on young healthy porcine
coronary arteries, not representative for atherosclerotic human
coronary arteries. It should be noted that the coronaries
of juvenile pigs endothelialize more rapidly following
injury. However, being similar to humans, the anatomy
and pathophysiology of porcine coronary arteries make this
PCI-model well accepted and established for basic and pre-
clinical translational research (7). OCT assessment of peri-strut
tissue burden was semiquantitative. Endothelialization was
assessed by light microscopy and not by scanning electron
microscopy. For the vasomotor responses we used 4mm vessel
rings, however we did not normalize the contraction with the
dry weight of the vessel ring. Finally, in the present study, we
utilized a third generation thin strut DES with biodegradable
polymer (8). Such stents were associated with low restenosis
and thrombosis rates as compared to early generation DES
(8). This might have contributed to the different results
obtained in our study compared with previous investigations
(18, 31).
CONCLUSION
Short-term peri-interventional triple therapy with dabigatran,
aspirin, and clopidogrel led to an enhanced endothelium
dependent vasodilation and faster endothelialization,
however, not reducing neointimal formation 1-month
after stent implantation, even if endothelialization
was complete.
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NOMENCLATURE
DES, drug-eluting stent(s)
DAPT, dual antiplatelet therapy
LAD, left anterior descending coronary artery
LCX, left circumflex coronary artery
MCP-1, monocyte chemoattractant protein 1
NOAC, non vitamin K antagonist oral anticoagulant
OCT, optical coherence tomography
PCI, percutaneous coronary intervention
PAR-1, protease activated receptor 1
QCA, quantitative coronary angiography
VSMC, vascular smooth muscle cells.
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